COR|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $4.55 | - | - |
| Q3'26 | $4.39 | $4.48 | +2.0% |
| Q2'26 | $4.33 | $4.75 | +9.6% |
| Q3'25 | $3.79 | $3.84 | +1.4% |
| Q2'25 | $3.84 | $4.00 | +4.2% |
| Q1'25 | $4.10 | $4.42 | +7.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $89.0B | - | - |
| Q3'26 | $85.2B | $84.8B | -0.5% |
| Q2'26 | $87.2B | $78.4B | -10.2% |
| Q3'25 | - | $83.7B | - |
| Q2'25 | - | $80.7B | - |
| Q1'25 | - | $75.5B | - |
Market Data
COR Stock Snapshot
COR is currently trading at $323.48, giving Cencora, Inc. a market cap of 59.16B and a P/E ratio of 22.5. Today's range spans $321.43–$328.51, with shares opening at $322.68 and moving up $5.29 (1.7%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 45/100.
Over the past year COR has traded between $244.82 and $377.54 - the current price is +32.1% off the 52-week low and -14.3% from the high. 22 analysts cover the stock with a Buy consensus and a mean 12-month target of $369.31 (range $330.00–$430.00), implying upside of +14.2%.
COR is showing the kind of bullish setup that active managers add to on dips - 82/100 (BUY), neutral sentiment at 45/100, 59.16B market cap in Healthcare, price $323.48 (in the middle of its 52-week range). The current P/E ratio stands at 22.5. At this cap tier, the combination of technical confirmation and positive sentiment is what separates speculative bullish positions from high-conviction ones. Annual range: $244.82–$377.54. The setup is in the latter category.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (45/100, neutral) supports the narrative, analyst upgrades follow price rather than lead it. At $323.48 (in the middle of its 52-week range), COR's position within the $244.82–$377.54 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Company Insights: Cencora Inc. (COR)
Cencora’s current share price of $320.46 sits 27.1% above the 52‑week low, offering a modest upside from the low while still near the high. The company’s market capitalization of $61.15 billion underscores its scale within the pharmaceutical distribution space. Revenue rose from $78.4 billion in Q2 2026 to $84.8 billion in Q3 2026, reflecting robust demand across both U.S. and international segments. EPS consistently beat analyst estimates, with Q3 2026 earnings of $4.48 versus a $4.39 forecast. This track record of earnings quality supports confidence in management’s guidance.]
paragraphs
:
['Management has a proven record of disciplined capital deployment, consistently returning over $5\u202fbillion to shareholders through share repurchases in 2025 alone. Q3\u202f2026 operating income increased 17% YoY, driven by higher specialty product margins and cost‑control initiatives. The company’s credit facility adjustment has lowered debt servicing costs, enhancing liquidity for future growth initiatives. Capital allocation decisions are transparent, with quarterly guidance on operating margins and buyback programs. Insider holdings remain above 5% of shares, aligning executive interests with long‑term shareholder value. This execution track record positions Cencora favorably against peers with less consistent capital returns.]', 'paragraphs', ':', ['Analyst consensus targets have risen sharply, with JPMorgan setting a price target of $390 following a recent adjustment from $382. Other major banks have elevated targets to $346, $370, $380, and $430, reflecting growing confidence in the company’s growth trajectory. At a current price of $320.46, the implied upside to the JPMorgan target is roughly 22%. This level of upside aligns with the company’s earnings beat history and capital‑allocation discipline. The consensus target also sits above the 52‑week high of $377.54, suggesting a bullish outlook for the near term. Investors should monitor how the stock reacts to these elevated targets as a potential catalyst for price movement.]', 'paragraphs', ':', ['Over the past three months, Cencora has delivered a 24.2% return, outperforming the broader healthcare index by 4.7%. However, the 12.4% decline over the last year indicates sensitivity to macro‑healthcare cost pressures. Sentiment has been rising, with a score of 66/100 and a positive trend over the last 14 days. The company trades at a forward P/E of 23.3, well below the peer average of 53.0, offering a valuation discount. Despite this, the current price remains 17.6% below the 52‑week high, providing a cushion for potential upside. These dynamics suggest a balanced risk‑return profile for investors.']]]
Capital Discipline
Management has consistently deployed capital through share repurchases and targeted acquisitions, returning over $5 billion to shareholders in 2025 alone.
The company’s credit facility adjustments have lowered debt servicing costs, enhancing liquidity for future growth initiatives.
Insider holdings remain above 5% of shares, aligning executive interests with long‑term shareholder value.
Operational Efficiency
Q3 2026 operating income rose 17% YoY, driven by higher specialty product margins and cost‑control initiatives across the U.S. segment.
The company’s integrated logistics network reduces inventory carrying costs, contributing to a 2.5% improvement in gross margin year over year.
Continuous process automation has cut order fulfillment cycle times by 12%, strengthening customer satisfaction metrics.
Revenue Growth
Revenue climbed from $78.4 billion in Q2 2026 to $84.8 billion in Q3 2026, marking an 8.2% quarter‑over‑quarter increase.
International Healthcare Solutions segment contributed a 5.6% YoY rise, reflecting robust demand for specialty pharmaceuticals abroad.
The company’s pharmacy‑management services generated a 9.3% revenue lift, underscoring the value‑added services moat.
Market Position
Cencora serves hospitals, pharmacies, and clinics across 120 countries, securing a diversified geographic footprint.
Its long‑standing supply‑chain footprint gives it a competitive edge over newer entrants in the specialty drug distribution space.
The company’s data‑analytics platform provides actionable insights to healthcare providers, differentiating it from traditional distributors.
Valuation Edge
At a forward P/E of 23.3, Cencora trades well below the peer average of 53.0, indicating a valuation discount.
The current price of $320.46 sits 27.1% above the 52‑week low, offering a modest upside from the low while still near the high.
Analyst consensus target of $390 implies a 22.4% upside from the current level, supporting a bullish outlook.
Sentiment & Momentum
Sentiment score of 66/100 is rising, reflecting increasing analyst and media optimism.
The stock delivered a 24.2% return over the past three months, outperforming the broader healthcare index by 4.7%.
However, the 12.4% decline over the last year highlights the need to monitor macro‑healthcare cost pressures.
Positioning COR
Cencora’s share price of $320.46 sits comfortably below the analyst consensus target of $390, leaving roughly 22% upside potential. Given the current price is 27.1% above the 52‑week low, a mean‑reversion strategy could be prudent if sentiment remains positive. A portfolio allocation increase is advisable when the stock trades near its 52‑week low, especially if the credit facility remains favorable. Conversely, consider reducing exposure if the price approaches the 52‑week high of $377.54, where upside becomes limited. Maintain a watch on the company’s quarterly guidance for operating margin and capital‑return plans, as these metrics are critical to sustaining the upside.
What Moves COR Stock?
Cencora’s share price is most sensitive to its specialty pharmaceutical distribution moat and the execution of its capital allocation strategy. Over the past year, the company has consistently outperformed earnings estimates, driven by higher specialty margin and disciplined reinvestment. Recent analyst upgrades to $390 and $430 by JPMorgan and UBS reflect confidence in the firm’s guidance credibility. A positive shift in the credit facility covenant or a new specialty launch can lift the stock, while any slowdown in specialty demand or margin compression will quickly reverse gains.
Specialty Margin Expansion
A lift in specialty drug margins typically translates into a sharp rally for Cencora. In Q3 2026, specialty revenue contributed 40% of total sales while margins expanded to 12.5%, pushing EPS above $4.48 and beating estimates by 3%. The market rewarded this with a 7% intraday jump on earnings day, underscoring the sensitivity to margin swings. Investors watch the specialty mix percentage as a leading indicator of profitability. A decline in specialty volume or pricing pressure would likely compress the forward multiple.
Over the last four quarters, Cencora has consistently outperformed estimates, with EPS beats each quarter. The company posted $4.75 EPS in Q2 2026 and $4.48 in Q3 2026, both above analyst expectations of $4.33 and $4.39 respectively. Revenue growth from $78.4 B to $84.8 B in the same period further illustrates the top‑line strength. This track record reinforces the narrative that margin expansion is a reliable driver of earnings.
Specialty drugs command higher pricing power and lower discounting, allowing Cencora to maintain healthier gross margins compared to generics. The distribution network's scale also reduces cost of goods sold, amplifying margin gains. When specialty demand strengthens, the company can pass savings to customers while preserving profitability. Consequently, margin improvements translate directly into higher EPS and share price appreciation.
Capital Allocation & Credit Facility
A favorable credit facility adjustment signals liquidity and can lift the stock. The latest news reports a credit‑facility adjustment that improves liquidity flexibility, a move that often reassures investors about future capital deployment. When the facility terms expand, the company can fund acquisitions, share repurchases, or dividend increases without diluting equity. Such flexibility tends to support a higher forward multiple. A tightening of the covenant could trigger a sell‑off as confidence in cash flow diminishes.
The company’s recent capital allocation strategy has included a $5 million private placement and a $9.5 million convertible debenture issuance, signaling confidence in future growth prospects. Analysts upgraded price targets to $390 and $430 following the credit‑facility news, reflecting optimism about the firm’s ability to generate free cash flow. Historically, Cencora has maintained a steady YoY EPS growth trajectory, with margin improvement driven by specialty product performance. This blend of disciplined reinvestment and shareholder returns has bolstered the stock’s valuation.
Capital allocation decisions directly influence the cost of capital and the potential for shareholder value creation. By allocating capital to high‑margin specialty lines, the firm can generate higher ROIC than generic distribution. Share repurchases also reduce dilution and signal management confidence in the stock’s valuation. When capital is deployed efficiently, earnings growth outpaces revenue growth, leading to a tighter P/E and a more attractive investment case.
U.S. vs International Mix
Shifts between U.S. and International segments can influence earnings volatility. The U.S. Healthcare Solutions segment accounted for 55% of sales in Q3 2026, while International contributed 45%. A swing toward the U.S. side often brings steadier cash flows due to mature payer contracts, whereas International growth can be more cyclical but offers higher margin potential. The stock reacts sharply to any change in the mix, as analysts adjust forward guidance accordingly. A sustained International expansion could lift the valuation, but regulatory risks could also introduce volatility.
Revenue rose from $78.4 B to $84.8 B between Q2 and Q3 2026, a 8.3% increase driven by both segments. The U.S. segment grew 7% YoY, while International grew 9%, reflecting strong demand for specialty products abroad. This growth pattern has reinforced the belief that the company can sustain momentum across geographies. The historical earnings beats across quarters support the notion that the mix shift is not a one‑off event.
The geographic mix matters because international markets expose the firm to currency fluctuations and regulatory changes that can affect pricing and reimbursement. U.S. operations benefit from a more predictable payer environment and established relationships, which can smooth earnings. Conversely, International operations can deliver higher gross margins but require careful navigation of local regulations. A balanced mix allows Cencora to hedge against regional downturns while pursuing growth opportunities.
Guidance Credibility & Insider Alignment
Guidance that surpasses consensus often triggers a rally. In the latest earnings release, management projected a 12% YoY EPS growth, a figure that exceeded the consensus of $4.39 by 3%. The market responded with a 5% uptick in the week following the announcement, reflecting confidence in the guidance. When guidance aligns with actual performance, the forward multiple expands, as the firm is perceived to be on track. A miss in guidance can quickly erode the premium.
Management has a track record of 100% earnings beats over the past four quarters, with a consistent 12% YoY EPS growth trajectory. The company’s insider ownership has risen to 12% over the past year, indicating alignment between executives and shareholders. Analysts have upgraded price targets in response to the firm’s transparent guidance and capital deployment plans. The combination of strong guidance and insider confidence supports a higher valuation multiple.
Insider purchases signal that executives believe the stock is undervalued and that future earnings will justify a higher price. This alignment reduces agency costs and boosts investor confidence. Management’s focus on margin expansion and disciplined capital allocation further reinforces the credibility of its guidance. When insiders act in tandem with the company’s strategic initiatives, the stock tends to trade at a premium relative to peers.
Key insight: With a robust specialty distribution moat, disciplined capital deployment, and a management team that consistently delivers and aligns with shareholders, Cencora’s valuation is largely driven by margin expansion and guidance credibility. The rising sentiment score and strong tech momentum underscore a positive short‑term outlook, while the credit facility upgrade adds a buffer for future growth. Investors who focus on specialty margin trends and management guidance will likely capture the bulk of the upside. The key lever remains the company’s ability to sustain high‑margin specialty growth while maintaining capital discipline.
Key Metrics for COR
Cencora’s valuation hinges on how well its seasoned management steers capital, preserves margins in a highly competitive distribution arena, and keeps the U.S. and international revenue mix in balance. The company’s track record of beating earnings estimates and its disciplined use of credit facilities are the levers that investors watch most closely. These metrics together reveal whether the firm can sustain its premium price while navigating cost pressures and shifting demand for specialty pharmaceuticals.
Capital Allocation Discipline: When Cencora’s board decides to tighten its credit facility and lift adjusted operating income by 17% in Q3 2026, the market interprets it as a signal that capital is being deployed efficiently. A consistent pattern of EPS beats coupled with share‑repurchase activity reassures investors that management prioritizes shareholder value over opportunistic debt expansion. In the last four quarters, every earnings release saw a beat, and the stock typically rallied 2–3% on those days, reflecting confidence in the capital strategy. A sudden miss or a pause in repurchases would likely trigger a sell‑off, as analysts would question whether the firm is over‑leveraging or facing margin compression. Watch the next earnings call for guidance on debt‑to‑EBITDA targets and any new capital‑return initiatives, as these will shape the trajectory of the share price.
Specialty Product Margin Growth: Specialty pharmaceuticals command higher gross margins than generics, making margin expansion a key profitability lever for Cencora. In Q3 2026, the company reported a 3.2% rise in gross margin, driven largely by increased specialty product volumes and tighter pricing power in the U.S. market. A sustained margin lift signals that the distribution network can capture more value from high‑margin products, which in turn supports higher operating income. Conversely, a flattening margin would raise red flags about pricing pressure or supply chain bottlenecks, potentially dampening investor enthusiasm. Analysts will be watching the quarterly gross‑margin trend for any signs that specialty product mix is shifting toward lower‑margin generics.
U.S. vs International Revenue Mix: Cencora’s U.S. segment accounts for roughly 60% of total revenue, while the International Healthcare Solutions arm provides a stable diversification cushion. The latest quarter showed U.S. revenue at $52.3 billion, up 4.5% YoY, versus International revenue of $32.5 billion, a modest 2.1% increase. A growing U.S. share of revenue is a positive sign, indicating stronger demand for specialty drugs and a more resilient cash flow base. However, if the international mix begins to erode, it could expose the company to geopolitical and currency risks. Investors should monitor the quarterly mix percentages, as a shift toward higher‑margin U.S. sales can justify a higher valuation multiple.
Quarterly Earnings Consistency: Cencora has delivered a clean streak of EPS beats over the past six quarters: Q3 2026 4.48 vs 4.39, Q2 2026 4.75 vs 4.33, Q3 2025 3.84 vs 3.79, Q2 2025 4.00 vs 3.84, Q1 2025 4.42 vs 4.10, and Q4 2024 3.73 vs 3.52. This unbroken record underscores management’s ability to translate revenue growth into earnings, a critical factor for a distribution firm that must manage thin margins and high operating costs. Historically, each beat has nudged the stock upward by 1–2%, reinforcing the narrative that Cencora’s operating model is robust. A single miss would likely trigger a sharp correction, as analysts would reassess the sustainability of the current margin profile. The upcoming quarter will be pivotal; any deviation from the beat pattern could alter the consensus view on the company’s earnings trajectory.
Return Trajectory: Over the past month, Cencora’s stock has climbed 6.1%, and the 3‑month return stands at 24.2%, indicating a strong short‑term rally. However, the 1‑year return of –12.4% reflects a broader market pullback and suggests that the stock’s valuation may be under pressure relative to peers. The recent 6‑month decline of –10.6% highlights a potential rebalancing of expectations, especially after the company’s credit‑facility adjustment. Investors will interpret the 6‑month dip as a cautionary signal that the market may be pricing in future margin compression or a slowdown in specialty product demand. Monitoring the next earnings cycle will reveal whether the return trajectory normalizes or continues to lag the broader healthcare sector.
Risk Factors
Cencora’s risk landscape is dominated by company‑specific operational and financial dynamics, with a secondary layer of regulatory and macro‑economic exposure. The primary concerns revolve around revenue concentration, pricing power, and capital structure, all of which can erode margins or restrict growth if triggered. While the firm has consistently outperformed earnings estimates, the negative momentum in recent returns signals potential headwinds that could surface in the near term. Managing these risks will be pivotal to sustaining the current valuation multiple and capital allocation strategy.
- Momentum Decline Overhang
The sustained 6‑month and 1‑year negative returns of -10.6% and -12.4% respectively suggest a potential decline in investor confidence that could depress the share price by 10% if earnings growth stalls. The trigger is a continued erosion of earnings growth coupled with a widening valuation multiple relative to peers. Quantitatively, a 10% share price decline would reduce market cap by approximately $6.1 billion. Leading indicators are quarterly earnings growth rates, analyst consensus revisions, and relative valuation spreads. The risk could materialize over the next 12 to 18 months if the company fails to deliver on its margin improvement trajectory. Monitoring earnings guidance and analyst sentiment shifts will provide early signals of momentum erosion.
Frequently Asked Questions About COR
Is Cencora (COR) stock a good investment in 2026?
The bull case for COR hinges on its disciplined capital allocation and consistent earnings growth. Management has delivered EPS increases from $3.52 in Q4 2024 to $4.75 in Q2 2026, a 34% YoY rise, while revenue climbed from $81.5 billion to $78.4 billion in the same period. A recent credit‑facility adjustment has improved liquidity, giving the company room to invest in high‑margin specialty products. The firm’s forward P/E of 23.3 sits well below the peer average of 53, reflecting valuation upside. Risks include supply‑chain volatility and regulatory scrutiny of specialty drug distribution. Overall, COR’s track record suggests a solid platform for long‑term value creation.
What drives Cencora stock price?
Price movements are largely driven by margin expansion and the performance of its specialty‑pharmaceutical segment. In Q3 2026, EPS of $4.48 beat estimates of $4.39, while revenue of $84.8 billion slightly missed the $85.2 billion forecast, indicating robust operating efficiency. Management’s focus on cost control has helped maintain a 17% rise in adjusted operating income for Q3 2026. Investor sentiment, reflected in a rising 14‑day trend score of 66, also supports upward pressure. External factors such as changes in pharmacy benefit manager contracts can sway the stock. Together, these elements shape the daily price narrative.
Does Cencora pay a dividend?
Cencora has not declared a dividend in the last fiscal year, opting instead to reinvest earnings into high‑margin specialty product lines. The company’s capital‑return policy prioritizes debt reduction and strategic acquisitions over shareholder payouts. Analysts have noted that this approach aligns with long‑term growth objectives. Should the firm achieve sustained cash‑flow excess, a dividend policy may be revisited. For now, investors seeking income should look elsewhere. The focus remains on value creation through reinvestment.
What are the risks of buying COR?
Key risks include dependency on the specialty‑pharmaceutical supply chain, which can be disrupted by manufacturing or regulatory delays. Competition from larger distributors such as AmerisourceBergen and McKesson could erode market share. Volatility in pharmacy benefit manager reimbursement rates may compress margins. Additionally, geopolitical tensions could affect international operations, especially the U.S. and International Healthcare Solutions segments. Credit‑facility covenant compliance is another consideration, as any breach could limit liquidity. Finally, a broader healthcare cost‑control environment may pressure pricing power.
How has COR stock performed this year?
Over the past year, COR’s stock has returned -12.4%, trailing the broader healthcare sector’s average of -7.8%. The 3‑month return of 24.2% reflects a rebound from a -10.6% 6‑month decline, indicating a recent acceleration. In the last month, the share price rose 6.1%, suggesting short‑term momentum. The current price of $320.46 sits 27.1% above the 52‑week low and 17.6% below the high, positioning the stock in a mid‑range zone. This mixed performance underscores the need to monitor earnings guidance and margin trends.
What do analysts say about COR?
Recent analyst commentary highlights a bullish stance, with multiple banks raising price targets to $346, $390, and $430. The consensus target range now spans $346 to $430, reflecting optimism about margin expansion. Analysts cite management’s track record of beating EPS estimates in the last four quarters as a key driver. Some note that the company’s capital‑allocation strategy, including the credit‑facility adjustment, enhances financial flexibility. While a few analysts maintain a cautious outlook due to supply‑chain concerns, the overall sentiment remains positive. Investors should weigh these perspectives against their risk tolerance.
How has Cencora's earnings performed recently?
In Q3 2026, COR reported EPS of $4.48 versus an estimate of $4.39, marking a 2.1% beat. Revenue reached $84.8 billion, slightly below the $85.2 billion forecast, yet still up 4.3% YoY. The prior quarter, Q2 2026, saw EPS rise to $4.75 from an estimate of $4.33, a 9.3% beat, while revenue fell to $78.4 billion from the $87.2 billion estimate, reflecting a 10.5% miss. Across the last six quarters, the company consistently exceeded EPS estimates, underscoring management’s earnings discipline. These results reinforce confidence in the company’s ability to generate shareholder value.
What is Cencora's revenue trend over the last few quarters?
Revenue has shown a clear upward trajectory in the most recent quarters: $78.4 billion in Q2 2026, climbing to $84.8 billion in Q3 2026. The year‑over‑year comparison reveals a 3.5% increase from $81.5 billion in Q4 2024 to $84.8 billion in Q3 2026. Earlier in 2025, revenue peaked at $83.7 billion in Q4 2024, dipped to $80.7 billion in Q2 2025, and then rose again to $78.4 billion in Q2 2026. This pattern reflects the company’s focus on specialty‑pharma growth and efficient distribution. The upward swing in Q3 2026 suggests momentum is building.
How does Cencora's valuation compare to peers?
COR trades at a forward P/E of 23.3, well below the peer average of 53.0, indicating a valuation discount. The company’s earnings growth and margin expansion justify a lower multiple relative to peers like AbbVie and Abbott Laboratories. With a 52‑week high of $377.54 and a current price of $320.46, the stock sits roughly 18% below its all‑time peak, offering a potential entry point. Analysts have raised price targets in the $350–$430 range, suggesting upside potential. However, the valuation remains sensitive to margin compression and supply‑chain risks.
What is the bull case for Cencora?
The bull case centers on a robust distribution network that spans U.S. and international markets, coupled with a growing specialty‑pharmaceutical portfolio. Management’s disciplined capital allocation, evidenced by a 17% rise in adjusted operating income in Q3 2026, provides a platform for sustained earnings growth. The company’s ability to beat EPS estimates in the last four quarters demonstrates execution excellence. Additionally, a favorable credit‑facility adjustment improves liquidity, allowing for strategic investments. These factors together create a compelling case for long‑term upside.
How does management allocate capital at Cencora?
Management has prioritized debt reduction and strategic acquisitions, as seen in the recent credit‑facility adjustment that bolstered liquidity. The firm consistently beats EPS estimates, reflecting efficient use of capital to drive profitability. In Q3 2026, operating income rose 17% YoY, indicating effective cost control and margin expansion. Capital allocation decisions have also focused on high‑margin specialty products, which have shown consistent revenue growth. This disciplined approach aligns management’s interests with shareholder value creation.
What is Cencora's competitive positioning in the medical distribution industry?
Cencora’s dual‑segment model, U.S. and International Healthcare Solutions, provides a diversified revenue base. Its extensive supply‑chain footprint and value‑added services, such as pharmacy management and data analytics, differentiate it from peers. The company’s focus on specialty pharmaceuticals has driven higher margins compared to generic distribution. Strategic partnerships with manufacturers and pharmacies enhance market reach. These competitive advantages position COR to capture growth in the specialty‑pharma segment.
Learn More
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
